Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers
The FDA has granted accelerated approval to Merus’ Bizengri in the treatment of advanced, unresectable NG1+ lung and pancreatic cancers.
The FDA has granted accelerated approval to Merus’ Bizengri in the treatment of advanced, unresectable NG1+ lung and pancreatic cancers.
What's Your Reaction?
